Who is winning the brain-chip race?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
Neuralink is winning the brain-chip race today, although Neuracle reached the commercial market first and Synchron may have the easiest route to widespread hospital adoption.
The field does not have one uncontested leader because each company is optimizing a different trade-off. Neuralink leads performance and breadth, Neuracle leads approved motor assistance, Synchron leads surgical simplicity, and Precision Neuroscience leads total patient exposure.
Neuralink’s 21 reported participants matter more than the raw number suggests. They form the largest modern cohort using a fully implanted, wireless, general-purpose interface over months and at home, which is a tougher test than a short recording session during surgery.
Precision’s more than 95 patient exposures are still important, but they answer a different question. They show that the company can work repeatedly inside hospitals and collect data from many brains; they do not yet prove that its permanent system can support everyday use.
Neuracle’s commercial lead came from choosing a narrower problem. An eight-electrode implant that triggers a robotic glove is less ambitious than fast cursor control or natural speech, but the focused benefit made approval, reimbursement and routine hospital use achievable sooner.
Synchron may eventually turn lower bandwidth into a commercial advantage. A catheter-based procedure that avoids open-brain surgery could reach far more hospitals and patients than a technically stronger implant that requires specialist neurosurgery and custom robotics.
NeuroXess is the most credible fast-rising outsider. Its reported 5.2-bit-per-second result and fully implanted wireless design put it closer to Neuralink than most challengers, but the evidence still rests on very few disclosed users and mostly company-reported results.
Paradromics is pursuing one of the most valuable applications—speech restoration—but it has only recently entered chronic human testing. Its technical design is promising; its ranking cannot move much until a participant communicates reliably outside the lab.
Funding efficiency is unusually hard to compare here. A temporary intraoperative array, a permanent home implant and an approved robotic-glove system carry completely different clinical and support costs, so simple dollars-per-patient ratios can be badly misleading.
Neuralink’s lead is real but not secure. It stays first as long as its high-performance threads remain reliable and regulation keeps moving; a safer rival that gets close enough on performance could change the market surprisingly quickly.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
Which brain-chip startups actually belong in this race?
The serious implantable brain-chip race currently includes seven companies, although only Neuralink, Neuracle, Synchron and Precision Neuroscience have built a strong case for leadership.
We include startups developing implanted brain-computer interfaces that let people control computers, robotic devices or their own assisted movements. Neuralink, Synchron, Precision Neuroscience, Neuracle Technology, NeuroXess and Paradromics all fit that definition. We also include Blackrock Neurotech because its technology has been implanted in people for far longer than the newer platforms, even though the company now looks more like a clinical veteran than a fast-moving startup.
We leave out consumer EEG headsets, research projects without a commercial company and non-invasive startups such as Merge Labs. Science Corporation also sits outside the main ranking. Its PRIMA retinal implant has produced impressive vision-restoration results, but a retinal prosthesis competes in a different clinical market from implants that decode movement or speech.
Private funding data remain uneven, particularly for Chinese companies. Public databases put Neuralink at roughly $1.3 billion raised, compared with $345 million for Synchron and $155 million for Precision. Paradromics has disclosed more than $105 million in venture funding plus approximately $18 million in government grants. Blackrock received a $200 million strategic investment from Tether, while reliable cumulative totals for Neuracle and NeuroXess remain unavailable.
| Startup | What the brain-chip startup is building | Publicly identified capital |
|---|---|---|
| Neuralink | Fully implanted wireless interface for computer, robotic-arm and future speech control | About $1.3B |
| Synchron | Endovascular interface inserted through the jugular vein | About $345M |
| Precision Neuroscience | High-density flexible array placed on the brain’s surface | About $155M |
| Paradromics | Penetrating high-bandwidth implant initially focused on speech restoration | More than $105M, plus about $18M in grants |
| Neuracle Technology | Epidural implant that turns intended hand movement into robotic-glove control | Cumulative total undisclosed |
| NeuroXess | Fully implanted wireless surface interface for digital control and speech decoding | Cumulative total undisclosed |
| Blackrock Neurotech | Utah Array platform with decades of human research use | $200M strategic investment; lifetime total undisclosed |
Is any brain-chip startup clearly ahead today?
Neuralink is the overall brain-chip leader today, but its lead is in high-performance general-purpose control, not every part of the market.
The company has the largest reported cohort using a modern, fully implanted general-purpose interface over extended periods. Neuralink participants have controlled computers, games and robotic arms, while several users have reached cursor speeds around the range of an able-bodied person using a mouse. Its system also combines implanted electronics, flexible threads, wireless transmission, decoding software and a purpose-built surgical robot.
Three rivals lead on narrower but commercially important questions. Neuracle reached regulatory approval and recently completed the first commercial implantation of its NEO system. Synchron offers the simplest surgical route because its implant travels through a blood vessel. Precision has already used its cortical arrays in more than 95 patients through over 15 hospital partners.
So the field has one overall leader, three specialist leaders and several credible challengers. Neuralink has pulled ahead on breadth and demonstrated capability. Neuracle leads commercialization, Synchron leads surgical practicality, and Precision leads early hospital exposure. Neuralink would look much harder to catch if it also held those three advantages.
If you want more recent data on this point, please see our latest neurotechnology market report.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Which brain-chip startup has the most human evidence?
Precision Neuroscience has used its brain-chip technology in the most patients, while Neuralink has built the strongest chronic cohort for broad computer and device control.
Precision reports more than 95 implanted clinical-study patients. Its headline count is roughly four and a half times Neuralink’s reported 21 participants. The comparison needs care because many Precision patients received the array temporarily during another neurosurgical procedure. The FDA-cleared Layer 7-T electrode is authorized for temporary use of less than 30 days, and published studies have largely involved short intraoperative recording sessions.
Neuralink’s smaller group provides more relevant evidence for an implant meant to remain in the body and work at home. Its participants use a fully implanted wireless system over months rather than minutes, hours or several days. That makes Neuralink’s patient count more valuable for judging long-term usability, even though Precision has collected data from many more individual brains.
Neuracle has completed 36 procedures, consisting of four feasibility cases and a 32-person multicentre study. Synchron’s first two studies covered ten people across Australia and the United States, with one-year safety follow-up. Blackrock brings decades of implant experience, but much of that evidence came through academic research systems rather than a finished modern consumer-facing product.
The cleanest reading is that there are three human-evidence leaders. Precision leads total patient exposure, Neuralink leads chronic general-purpose usage, and Neuracle leads the evidence package attached to an approved product.
Did Neuracle really beat Neuralink to the brain-chip market?
Yes. Neuracle beat Neuralink to commercial brain-chip use by getting a focused motor-assistance product approved and implanted outside a clinical trial.
China’s regulator approved Neuracle’s NEO system in March 2026 for adults with severe paralysis caused by cervical spinal-cord injuries. NEO uses eight electrodes placed above the brain’s protective membrane. When a user imagines moving a hand, the system translates that intention into commands for a pneumatic glove. The company recently completed its first commercial procedure after the product received regulatory registration, medical-service coding and local insurance pricing clearance.
Neuracle got there through a deliberately narrow product. The company tested NEO in 36 procedures, and the 32-person formal study reported improvements in grasping function across the participating patients. An eight-electrode system controlling a glove asks less of the brain interface than natural speech decoding or fast, multidimensional computer control. That smaller target made the clinical benefit easier to define and the regulatory path easier to finish.
Neuralink remains in clinical trials and has yet to disclose product revenue. Synchron is preparing larger trials, Paradromics has only recently placed its first chronic Connexus implant, and Precision’s clearance covers a temporary cortical electrode rather than its complete permanent system.
Neuracle won the first commercial round. Neuralink still leads the broader platform race, but the claim that every serious competitor remains confined to experiments is now plainly wrong.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Is Neuralink the best-performing brain-chip startup today?
Neuralink currently has the strongest public performance evidence among brain-chip startups with fully implanted systems used over time.
The company’s latest update says multiple participants have reached or exceeded eight to ten bits per second on its cursor-control task, roughly the range achieved by able-bodied people using a conventional mouse. One participant recorded 10.39 bits per second, while Neuralink’s first participant had previously progressed from 4.6 to 8 bits per second. These tests come from Neuralink rather than an independent head-to-head study, but they show repeat performance across more than one person.
NeuroXess is the closest numerical challenger. The Chinese startup says its first fully implanted wireless participant reached 5.2 bits per second after 17 days of training, allowing web browsing, gaming and external-device control. On the published numbers, Neuralink’s best result is approximately twice as fast. NeuroXess’s result remains company-reported and comes from a much smaller public sample, so the ratio is not a clean clinical benchmark.
Precision has demonstrated far greater electrode density. Its standard array carries 1,024 electrodes, and one procedure used four arrays with 4,096 electrodes. Published human work has shown real-time cursor control and speech classification, although those tests took place during limited intraoperative sessions. High channel count gives Precision considerable potential, but chronic performance has not caught up with the hardware specifications.
Paradromics has implanted its first long-term Connexus participant and plans to measure speech, vocabulary, words per minute and data throughput over several years. Its 421 penetrating microelectrodes could eventually support richer speech decoding, but the company has not released a chronic human speech result from Connexus.
Neuralink deserves the performance lead because it combines speed, repeated users and chronic operation. Precision and Paradromics still offer more potential than proof, while NeuroXess needs replication across additional participants.
Which brain-chip startup works best in everyday life?
Neuralink has the clearest evidence of a brain chip becoming part of a person’s normal daily routine.
Neuralink participants use the implant to browse the web, work with design software, play complex games and operate computers at home. The company has also shown a participant controlling a robotic arm to feed himself and scratch his face. Those activities go beyond selecting targets in a laboratory test because they involve long sessions, changing software and tasks that users choose for themselves.
Synchron comes second on everyday usefulness. Its participants have controlled computers, smart-home devices and Apple products through the Stentrode. Synchron’s integration with Apple’s brain-computer-interface protocol has allowed a participant with ALS to navigate an iPad, open applications and compose messages without relying on touch, speech or eye tracking. The control system remains slower and more limited than Neuralink’s, but lower-bandwidth commands can still restore useful independence.
Neuracle’s product delivers a more physical but narrower benefit. NEO lets people with spinal-cord injuries activate a robotic glove and regain basic grasping ability. That can be life-changing, although it represents a small set of decoded intentions rather than open-ended control of software and machines.
Neuralink takes this category because its users have applied one implant across the widest range of self-directed activities. The evidence still leans heavily on company updates and selected participant stories. A peer-reviewed study covering independent home use across the full cohort would make the case much stronger.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Which brain-chip startup has the least invasive implant?
Synchron clearly has the least invasive implant among the leading brain-chip startups.
The Stentrode travels through the jugular vein and expands inside a blood vessel beside the motor cortex. Synchron says the clinical procedure takes around two hours and that most participants can return home the next day. Surgeons avoid opening the skull and placing electrodes directly into brain tissue.
That surgical advantage comes with weaker access to neural activity. Electrodes inside a blood vessel sit farther from individual neurons than Neuralink’s threads or Paradromics’ microwires. Synchron has already achieved useful digital control, but it has yet to demonstrate the speed and range of commands shown by Neuralink.
Precision takes the middle position. Its flexible array rests on the brain’s surface and can be inserted through a narrow microslit. Neuracle’s eight electrodes also sit above the dura rather than entering the cortex. Both approaches seek richer neural information than Synchron while avoiding the tissue penetration used by Neuralink and Paradromics.
| Startup | Where the electrodes sit | Relative surgical burden | Main compromise |
|---|---|---|---|
| Synchron | Inside a blood vessel beside the motor cortex | Lowest | Easier procedure with lower signal resolution |
| Precision Neuroscience | On the cortical surface | Low to moderate | High-density recording without chronic full-system proof |
| Neuracle Technology | Above the dura | Moderate | Approved clinical use with only eight electrodes |
| NeuroXess | On the cortical surface | Moderate | Promising wireless performance with limited long-term evidence |
| Neuralink | Flexible threads inside cortical tissue | Higher | Strong performance with greater surgical and mechanical complexity |
| Paradromics | Microwires penetrating cortical tissue | Higher | High potential bandwidth with one chronic participant |
Which brain-chip startup is moving fastest right now?
Neuracle has delivered the biggest recent brain-chip milestone, while Neuralink has created the broadest momentum across patients, products and applications.
Neuracle moved through four distinct steps that other startups still separate into future plans: a multicentre study, regulatory approval, reimbursement preparation and a commercial implantation. The sequence shows a functioning route from research to routine hospital treatment. One procedure does not create a large market, but the company has crossed a line that every American rival is still trying to reach.
Neuralink’s momentum has come from expansion rather than approval. Its reported participant base has grown from three people in an earlier update to 21 now. The company has extended its work from computer cursors into robotic arms and speech-related applications, while clinical activity has spread beyond its original US study. More chronic participants also give Neuralink more surgical experience and more data about how neural recordings change after months of use.
The chasing group has become more credible too. Paradromics completed its first chronic Connexus implantation. NeuroXess reported its first fully implanted wireless human system and began building a 14,300-square-metre production site. Precision passed 95 patient exposures and formed a partnership to integrate Layer 7 with Medtronic’s neurosurgical platform. Synchron raised a $200 million Series D and launched new studies around a more advanced version of the Stentrode.
Neuracle wins on the importance of its latest achievement. Neuralink wins on the number of fronts advancing at once. NeuroXess currently looks like the fastest-rising outsider, although its public evidence remains thinner and more dependent on company claims.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Which brain-chip startup can actually scale surgery and manufacturing?
Neuralink has the strongest resources for large-scale brain-chip production, while Synchron has the surgical model that should be easiest for hospitals to adopt.
Neuralink’s $1.3 billion funding base supports an unusually broad operation covering implant design, chip development, electrode production, software, clinical support and a dedicated surgical robot. The robot could standardize the placement of flexible threads and reduce reliance on a small number of surgeons with rare manual skills. It also creates another expensive medical system that Neuralink must manufacture, certify, install and maintain.
Synchron can use medical infrastructure that already exists. Hospitals routinely perform catheter-based vascular procedures, and the Stentrode avoids a purpose-built brain-surgery robot. A successful pivotal study could therefore give Synchron a much wider pool of implanting specialists than Neuralink or Paradromics. Surgical simplicity may compensate for lower neural bandwidth once hospitals and insurers start comparing total treatment costs.
Precision has built a 22,000-square-foot MEMS facility for manufacturing its electrode arrays and works with more than 15 hospitals. Its Medtronic partnership could connect Layer 7 with an established neurosurgical platform and sales network. Precision still needs to show that its complete permanent system can move from temporary hospital studies into repeated home use.
NeuroXess has announced the boldest factory plan. Its new 14,300-square-metre site is designed to support eventual annual production in the tens of thousands of implants and surgical robots. Announced capacity says little about regulatory-grade yield, sterilization, reliability or demand, so for now the facility proves ambition rather than scale.
Thousands of reliable annual implants remain beyond the evidence for every company. Neuralink is best equipped to spend its way through the bottlenecks. Synchron has the cleaner route to broad surgical distribution. Precision currently has the strongest combination of in-house electrode manufacturing and established medical partners.
If you want more recent data on this point, please see our latest neurotechnology market report.
What can the leading brain-chip startups do that rivals cannot easily copy?
Neuralink owns the deepest full-stack brain-chip advantage, while Synchron holds the most distinctive surgical advantage.
A new competitor could design a cortical electrode or train a neural-decoding model. Reproducing Neuralink would require flexible implanted threads, custom electronics, wireless charging and communication, surgical robotics, decoding software, clinical operations and long-term participant support. The company can also learn from a larger chronic user base than its direct high-performance competitors. Each additional participant produces data on electrode stability, user learning, software adaptation and daily usage.
Synchron’s protection comes from combining vascular medicine with neural decoding. The Stentrode involves stent design, catheter delivery, long-term blood compatibility and the ability to extract useful motor information from a relatively distant recording position. A cortical-interface company cannot obtain those benefits through a minor product redesign.
Precision has built expertise in extremely thin surface arrays, high-density microfabrication and microslit insertion. Its hospital network and Medtronic integration could become harder to copy than the electrode itself. Neuracle now owns practical knowledge of the Chinese approval, hospital-pricing and reimbursement process for an invasive BCI, along with the first approved installed base.
Paradromics is betting on very high data throughput from individual neurons, especially for speech. NeuroXess combines flexible surface electronics with a fully implanted wireless design and is collecting data from Chinese-speaking patients, an area where Western clinical datasets remain limited.
Neuralink has the broadest moat because its advantage spans the full product. Synchron’s vascular route may prove more durable commercially if buyers decide that a safer and easier procedure outweighs maximum performance.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Is Neuralink using its brain-chip funding efficiently?
Neuralink has turned approximately $1.3 billion into the broadest brain-chip platform, while Precision and Neuracle appear more efficient on narrower milestones.
Neuralink has raised nearly four times as much as Synchron, more than eight times Precision’s total and over ten times Paradromics’ venture funding. That capital has produced 21 reported participants, international trials, a surgical robot, high-speed cursor control and robotic-arm use. The output is substantial, but Neuralink should be far ahead given the size of its financial advantage.
Precision reached more than 95 patients, FDA clearance for its temporary array and over 15 hospital partners with $155 million raised. On a simple patient-exposure basis, Precision has used around one-eighth of Neuralink’s capital to work with more than four times as many people. That ratio flatters Precision because short intraoperative procedures cost far less than supporting permanent implants at home. Still, the company has collected a large human dataset without Neuralink-scale spending.
Neuracle may have achieved the best regulatory return on private capital, although the company’s full financing and public support are unclear. It reached approval after 36 procedures and then completed a commercial implantation. Chinese university resources, hospital infrastructure and government programs may have covered costs that never appeared in conventional venture-funding databases.
Synchron’s $345 million has produced strong safety evidence and the least invasive platform, but only ten participants were included in its first completed studies. Paradromics spent more than $100 million in venture capital before beginning its first chronic study. Both companies may ultimately justify that spending, though their current clinical output looks modest beside Neuralink, Precision and Neuracle.
We rank Neuralink first on total progress and Precision first on visible capital efficiency among the companies with reasonably transparent funding. Neuracle could be the true efficiency leader, but the public numbers are too incomplete for a confident ratio.
Which brain-chip startup leads each part of the market?
The brain-chip market currently has several leaders because the companies are solving different clinical problems with different surgical compromises.
Neuralink leads high-performance computer and robotic control. Its participants have achieved the strongest public cursor results among current startup systems and have used the same platform across digital and physical tasks. NeuroXess is the closest emerging challenger in this segment, with reported cursor control at 5.2 bits per second from a fully implanted wireless surface system.
Neuracle leads approved motor assistance. Its NEO implant has reached commercial use for people with paralysis who need help restoring hand grasp. The product covers fewer commands than Neuralink, but hospitals can now offer it within a regulated treatment pathway.
Synchron leads minimally invasive digital access. Its endovascular procedure gives it the best chance of reaching hospitals that would hesitate to adopt penetrating cortical implants. The company could become the volume leader even with lower performance if patients consistently prefer its risk-benefit trade-off.
Precision leads high-density surface recording and hospital exposure. More than 95 patients, over 15 clinical partners, a cleared temporary electrode and a Medtronic integration give the company a strong bridge between experimental BCIs and conventional neurosurgery. Chronic home performance remains its missing proof.
Paradromics is the most focused speech challenger. Its first chronic Connexus participant has a condition affecting speech, and the study will measure vocabulary, communication speed and data throughput. The company could jump several places if it produces fast, reliable speech outside the laboratory.
Blackrock remains the research-platform veteran. Its Utah Array helped establish that long-term intracortical BCIs can work in people, but newer startups have moved faster on wireless systems, easier implantation and product design. NeuroXess now deserves more attention than Blackrock in a forward-looking ranking because it has paired human performance with an explicit industrial-production push.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
Which brain-chip startups are actually ahead?
Neuralink is ahead overall, with Neuracle and Synchron emerging as its two closest challengers for very different reasons.
We give the most weight to chronic human use, useful performance, product breadth, clinical maturity and the ability to scale. Neuralink wins that combination. It has the best demonstrated general-purpose control, a growing participant base and a system that already spans computers and robotic devices. Its lead over NeuroXess on the strongest public cursor figures is roughly twofold, while its funding exceeds every direct competitor by a wide margin.
Neuracle ranks second because it has completed something more ambitious competitors have only discussed: moving an invasive BCI into commercial hospital use. Its product remains narrow, but approval, reimbursement preparation and a real commercial procedure carry more weight than another prototype demonstration.
Synchron ranks third because the Stentrode offers the strongest path toward broad adoption. A brain chip that works slightly less well can still win commercially when implantation is safer, faster and available through a much larger medical workforce. Synchron needs its new studies to show that the second-generation system can add richer control without losing that advantage.
Precision sits close behind Synchron. Its hospital reach, manufacturing facility, Medtronic partnership and patient exposure are impressive. The ranking could change quickly once Precision leaves the operating room with a permanent wireless system that people use independently at home.
NeuroXess has become the most dangerous outsider. Its 5.2-bit-per-second result, fully implanted wireless design and planned factory suggest a company moving from research into industrial execution. We hold it below Precision because the evidence comes from very few disclosed participants and remains largely company-reported.
Paradromics has a credible route into high-value speech restoration, but one chronic participant leaves too much unproven. Blackrock’s historical contribution remains enormous, although its slow product conversion now outweighs that legacy in a startup race.
Neuralink would lose first place if its penetrating threads continue creating reliability problems, if regulatory progress stalls, or if Synchron approaches its performance through a much simpler procedure. Neuracle could also move ahead by turning one commercial implantation into repeated hospital adoption and expanding beyond basic hand control.
For now, Neuralink is the most convincing overall brain-chip leader. Neuracle reached the market first. Synchron owns the strongest surgical model. The gap is real, but Neuralink has yet to turn technical leadership into an approved and repeatable business.
| Rank | Brain-chip startup | Why it ranks here |
|---|---|---|
| 1 | Neuralink | Strongest combination of chronic users, public performance, everyday use, platform breadth and funding |
| 2 | Neuracle Technology | First approved commercial invasive BCI, backed by 36 clinical procedures, but focused on basic hand control |
| 3 | Synchron | Least invasive implantation and the clearest path to broad hospital adoption, with lower current bandwidth |
| 4 | Precision Neuroscience | Largest patient exposure, strong hospital network and Medtronic partnership, but limited chronic home evidence |
| 5 | NeuroXess | Fast reported performance, fully implanted wireless design and serious manufacturing plans, with thin independent evidence |
| 6 | Paradromics | Promising high-bandwidth speech platform that has only recently entered chronic human testing |
| 7 | Blackrock Neurotech | Deepest historical research record, weakened by slow conversion into a modern scalable product |
If you want more recent data on this point, please see our latest neurotechnology market report.
OUR METHODOLOGY
This analysis asks who is winning the implantable brain-chip race today. We compare the companies across chronic human use, total patient exposure, real-world performance, regulatory and commercial progress, surgical practicality, manufacturing readiness, scalability and capital efficiency.
We define the field narrowly. The ranking includes commercial companies building implanted brain-computer interfaces that decode movement, speech or intended actions to control computers, robotic devices or assisted movement. We exclude consumer EEG products, non-invasive interfaces, academic projects without a commercial company, retinal prostheses and established public medical-device manufacturers.
For each question, we use the evidence that best fits the claim rather than treating every patient, procedure or performance result as equivalent. A temporary intraoperative recording session counts as human exposure, but it does not carry the same weight as a fully implanted system used wirelessly at home for months. Regulatory clearance for a temporary electrode is also different from approval of a complete permanent product.
Recent demonstrated progress receives more weight than historical reputation or announced capability. Company-reported results are included when they provide specific participant counts, procedures, performance figures or product milestones, but peer-reviewed studies, clinical-trial records and regulator documents receive greater weight when available.
Funding figures are treated as publicly identified capital rather than perfectly comparable lifetime totals. Private databases may combine equity, grants, debt and strategic investments differently, and disclosure is much thinner for Neuracle and NeuroXess than for the US companies. Capital-efficiency comparisons are therefore used as directional judgments, not precise financial ratios.
The final ranking is an aggregation of the evidence across the Q&A sections, not a hidden numerical score. It rewards companies that have repeated useful results in people, moved toward a real clinical product and built a plausible route to implantation at scale. A narrow approved product can therefore outrank a technically richer prototype, while a large temporary-study cohort does not automatically outrank a smaller chronic cohort.
Key sources include Neuralink’s official clinical and product updates, Neuralink’s Series E announcement, Synchron’s official materials, ClinicalTrials.gov study records, Precision Neuroscience’s official materials, Precision’s Series C announcement, Paradromics’ official materials, Blackrock Neurotech’s official materials, FDA device records, China’s National Medical Products Administration, Neuracle Technology’s official materials, NeuroXess’s official materials, Medtronic’s partnership and platform information, PubMed-indexed clinical research, Nature Biomedical Engineering, The New England Journal of Medicine and Science.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
Related blog posts
- Brain stimulation: which startup is ahead?
